Results 241 to 250 of about 99,136 (277)
Redox biomarker levels in patients with myelodysplastic syndrome. [PDF]
Biomed RepTsiara E +5 more
europepmc +1 more source
RBC transfusion dependency refines the Molecular International Prognostic Scoring System for myelodysplastic syndrome. [PDF]
Blood AdvWiseman T +12 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annals of the New York Academy of Sciences, 2004
Abstract: Efforts made during the last few years have helped unravel the complex pathogenesis of the myelodysplastic syndromes (MDS). A large number of studies, made possible by the introduction of newer technologies, have led to major progress in understanding the heterogeneous genetic and biological abnormalities contributing to the development and ...
CILLONI, Daniela +7 more
+8 more sources
Abstract: Efforts made during the last few years have helped unravel the complex pathogenesis of the myelodysplastic syndromes (MDS). A large number of studies, made possible by the introduction of newer technologies, have led to major progress in understanding the heterogeneous genetic and biological abnormalities contributing to the development and ...
CILLONI, Daniela +7 more
+8 more sources
Hematology and Cell Therapy, 1996
The authors review the epidemiological biological, diagnostic, prognostic and therapeutic aspects of myelodysplastic syndromes.
J F, San Miguel +4 more
+9 more sources
The authors review the epidemiological biological, diagnostic, prognostic and therapeutic aspects of myelodysplastic syndromes.
J F, San Miguel +4 more
+9 more sources
Hematology, 2003
AbstractThe last decade has witnessed a multistep evolution in the understanding of the natural history, clinical manifestations, and some of the molecular mechanisms that underlie the ineffective hematopoiesis and leukemic transformation in the myelodysplastic syndrome (MDS).
Mufti, G, List, A F, Gore, S D, Ho, A Y
openaire +2 more sources
AbstractThe last decade has witnessed a multistep evolution in the understanding of the natural history, clinical manifestations, and some of the molecular mechanisms that underlie the ineffective hematopoiesis and leukemic transformation in the myelodysplastic syndrome (MDS).
Mufti, G, List, A F, Gore, S D, Ho, A Y
openaire +2 more sources
International Journal of Hematology, 2005
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of
Shinji, Nakao +5 more
openaire +4 more sources
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of
Shinji, Nakao +5 more
openaire +4 more sources
Pathology Patterns Reviews, 2003
Myelodysplastic syndromes are a group of clonal hematopoietic stem cell disorders in which there is ineffective hematopoiesis. Affected patients are primarily elderly people, but also at risk are certain subsets of patients who have been exposed to antineoplastic chemotherapy and select patients with primary bone marrow failure syndromes such as ...
Phuong L, Nguyen, Yin, Xu, Aminah, Jatoi
openaire +2 more sources
Myelodysplastic syndromes are a group of clonal hematopoietic stem cell disorders in which there is ineffective hematopoiesis. Affected patients are primarily elderly people, but also at risk are certain subsets of patients who have been exposed to antineoplastic chemotherapy and select patients with primary bone marrow failure syndromes such as ...
Phuong L, Nguyen, Yin, Xu, Aminah, Jatoi
openaire +2 more sources
Nature Reviews Disease Primers, 2022
Myelodysplastic syndromes (MDS) are a family of myeloid cancers with diverse genotypes and phenotypes characterized by ineffective haematopoiesis and risk of transformation to acute myeloid leukaemia (AML). Some epidemiological data indicate that MDS incidence is increasing in resource-rich regions but this is controversial.
Huan Li +4 more
openaire +2 more sources
Myelodysplastic syndromes (MDS) are a family of myeloid cancers with diverse genotypes and phenotypes characterized by ineffective haematopoiesis and risk of transformation to acute myeloid leukaemia (AML). Some epidemiological data indicate that MDS incidence is increasing in resource-rich regions but this is controversial.
Huan Li +4 more
openaire +2 more sources
Hematology, 2002
AbstractThe myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency associated with cytopenias leading to serious morbidity plus the additional risk of leukemic transformation. Therapeutic dilemmas exist in MDS because of the disease’s multifactorial pathogenetic features, heterogeneous stages, and the patients’ generally elderly
Peter L, Greenberg +2 more
openaire +2 more sources
AbstractThe myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency associated with cytopenias leading to serious morbidity plus the additional risk of leukemic transformation. Therapeutic dilemmas exist in MDS because of the disease’s multifactorial pathogenetic features, heterogeneous stages, and the patients’ generally elderly
Peter L, Greenberg +2 more
openaire +2 more sources